Epidermal growth factor receptor and proliferating cell nuclear antigen expression in urine ThinPrep specimens

Cytopathology

Volumn 16, Issue 6, 2005, Pages 303-308

  Politi, Ekaterini N ^a,d   Lazaris, A C ^b   Lambropoulou, S ^c   Alexopoulou, D ^c   Kyriakidou, V ^a   Koutselini, H ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d NONE   (Greece)

Author keywords

Epidermal growth factor receptor; Proliferating cell nuclear antigen; ThinPrep; Urine cytology; Urothelial carcinoma

Indexed keywords

BIOLOGICAL MARKER; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; AUTOMATION; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CYTOLOGY; DIAGNOSTIC VALUE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMEAR; TISSUE SECTION; TRANSURETHRAL RESECTION; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CYTODIAGNOSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; URINARY BLADDER NEOPLASMS;

EID: 28944454958     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2005.00270.x     Document Type: Article

References (34)

1. Douglas RM, Kaufman DS, Zietman AL et al. Conservative surgery, patient selection, and chemoradiation as organ-preserving treatment for muscle-invading bladder cancer. Semin Oncol 1996;23:614-20.
2. Chow NH, Liu HS, Lee EI et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res 1997;17:1293-6.
3. Nguyen PL, Swanson PE, Jaszcz W et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 1994;101:166-76.
4. Ravery V, Colombel M, Popov Z et al. Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer. Br J Cancer 1995;71:196-200.
5. Olayioye MA, Neve RM, Lane HA et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
6. Prenzel N, Fischer OM, Streit S et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001;8:11-31.
7. Messing EM. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 1990;50:2530-7.
8. Wagner U, Sauter G, Moch H et al. Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. Hum Pathol 1995;26:970-8.
9. Messing EM. Growth factors and bladder cancer: clinical implications of the interactions between growth factors and their urothelial receptors. Semin Surg Oncol 1992;8:285-92.
10. Neal DE, Mellon K. Epidermal growth factor receptor and bladder cancer: a review. Urol Int 1992;48:365-71.
11. Thogersen VB, Jorgensen PE, Sorensen BS et al. Expression of transforming growth factor alpha and epidermal growth factor receptor in human bladder cancer. Scand J Clin Lab Invest 1999;59:267-77.
12. Paunesku T, Mittal S, Protic M et al. Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. Int J Radiat Biol 2001;77:1007-21.
13. Kelman Z. PCNA: structure, functions and interactions. Oncogens 1997;14:629-40.
14. Yu CC, Filipe MI. Update on proliferation-associated antibodies applicable to formalin-fixed paraffin-embedded tissue and their clinical applications. Histochem J 1993;25:843-53.
15. Cheng J, Huang H, Zhang ZT et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumour growth. Cancer Res 2002;62:4157-63.
16. Koyuncuoglu M, Kargi A, Cingoz S et al. Investigation of p53, c-erbB-2, PCNA immunoreactivity, DNA content, AgNOR and apoptosis in bladder carcinoma as prognostic parameters. Cancer Lett 1998;126:143-8.
17. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours, 5th edn. New York: John Wiley & Sons; 1997.
18. Kitazume H, Kitamura K, Mukai K et al. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining. Cancer 2000;90:55-60.
19. Schofield K, D'Aquila T, Rimm DL. The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluids. Cancer 1997;81:293-8.
20. Leung SW, Bedard YC. Immunocytochemical staining on ThinPrep processed smears. Mod Pathol 1996;9:304-6.
21. Dabbs DJ, Abendroth CS, Grenko RT et al. Immunocytochemistry on the Thinprep processor. Diagn Cytopathol 1997;17:388-92.
22. Linder J. Recent advances in thin-layer cytology. Diagn Cytopathol 1998;18:24-32.
23. Gong Y, Sun X, Michael CW et al. Immunocytochemistry of serous effusion specimens: a comparison of ThinPrep vs cell block. Diagn Cytopathol 2003;28:1-5.
24. Wilkinson EJ, Hendricks JB. Role of the pathologist in biomarker studies. J Cell Biochem Suppl 1995;23:10-8.
25. Tabbara SO, Sidawy MK, Frost AR et al. The stability of estrogen and progesterone receptor expression on breast carcinoma cells stored as PreservCyt suspensions and as ThinPrep slides. Cancer 1998;84:355-60.
26. Maurizi M, Almadori G, Ferrandina G et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 1996;74:1253-7.
27. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(Suppl. 4):S9-15.
28. Kersemaekers AM, Fleuren GJ, Renter GG et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999;5:577-86.
29. Inada S, Koto T, Futami K et al. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today 1999;29:493-503.
30. Mellon K, Wright C, Kelly P et al. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 1995;153:919-25.
31. Di Fiore PP, Pierce JH, Fleming TP et al. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 1987;51:1063-70.
32. Lavezzi AM, Biondo B, Cazzullo A et al. The role of different biomarkers (DNA, PCNA, apoptosis and karyotype) in prognostic evaluation of superficial transitional cell bladder carcinoma. Anticancer Res 2001;21:1279-84.
33. Kruger S, Muller H. Correlation of morphometry, nucleolar organizer regions, proliferating cell nuclear antigen and Ki67 antigen expression with grading and staging in urinary bladder carcinomas. Br J Urol 1995;75:480-4.
34. Bozlu M, Orhan D, Baltaci S et al. The prognostic value of proliferating cell nuclear antigen, Ki-67 and nucleolar organizer region in transitional cell carcinoma of the bladder. Int Urol Nephrol 2002;33:59-66.